These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35984030)

  • 1. Prebiotics and Probiotics: Effects on Dyslipidemia and NAFLD/NASH and the Associated Mechanisms of Action.
    Rodríguez-Pastén A; Fernández-Martínez E; Pérez-Hernández N; Soria-Jasso LE; Cariño-Cortés R
    Curr Pharm Biotechnol; 2023; 24(5):633-646. PubMed ID: 35984030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
    Koopman N; Molinaro A; Nieuwdorp M; Holleboom AG
    Aliment Pharmacol Ther; 2019 Sep; 50(6):628-639. PubMed ID: 31373710
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review.
    Carpi RZ; Barbalho SM; Sloan KP; Laurindo LF; Gonzaga HF; Grippa PC; Zutin TLM; Girio RJS; Repetti CSF; Detregiachi CRP; Bueno PCS; Mazuqueli Pereira ESB; Goulart RA; Haber JFDS
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
    Chen J; Thomsen M; Vitetta L
    J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics.
    Nagashimada M; Honda M
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
    Jiao TY; Ma YD; Guo XZ; Ye YF; Xie C
    Acta Pharmacol Sin; 2022 May; 43(5):1103-1119. PubMed ID: 35217817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives.
    Hu H; Lin A; Kong M; Yao X; Yin M; Xia H; Ma J; Liu H
    J Gastroenterol; 2020 Feb; 55(2):142-158. PubMed ID: 31845054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH).
    Duarte SMB; Stefano JT; Oliveira CP
    Ann Hepatol; 2019; 18(3):416-421. PubMed ID: 31036494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies.
    Ebrahimzadeh Leylabadlo H; Ghotaslou R; Samadi Kafil H; Feizabadi MM; Moaddab SY; Farajnia S; Sheykhsaran E; Sanaie S; Shanehbandi D; Bannazadeh Baghi H
    Eur J Clin Microbiol Infect Dis; 2020 Apr; 39(4):613-627. PubMed ID: 31828683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?
    Xie C; Halegoua-DeMarzio D
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway.
    Luo M; Yan J; Wu L; Wu J; Chen Z; Jiang J; Chen Z; He B
    J Immunol Res; 2021; 2021():2264737. PubMed ID: 34458376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Activity of Prebiotics and Probiotics in Hepatogastrointestinal Disorders and Diseases Associated with Metabolic Syndrome.
    Rodríguez-Pastén A; Pérez-Hernández N; Añorve-Morga J; Jiménez-Alvarado R; Cariño-Cortés R; Sosa-Lozada T; Fernández-Martínez E
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease.
    Miura K; Ohnishi H
    World J Gastroenterol; 2014 Jun; 20(23):7381-91. PubMed ID: 24966608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protective effects of Lactobacillus rhamnosus GG against dyslipidemia in high-fat diet-induced obese mice.
    Kim B; Park KY; Ji Y; Park S; Holzapfel W; Hyun CK
    Biochem Biophys Res Commun; 2016 Apr; 473(2):530-6. PubMed ID: 27018382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression.
    Gottlieb A; Canbay A
    Cells; 2019 Oct; 8(11):. PubMed ID: 31671697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.
    Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis.
    Delzenne NM; Knudsen C; Beaumont M; Rodriguez J; Neyrinck AM; Bindels LB
    Proc Nutr Soc; 2019 Aug; 78(3):319-328. PubMed ID: 30628563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mice lacking
    Gallo-Ebert C; Francisco J; Liu HY; Draper R; Modi K; Hayward MD; Jones BK; Buiakova O; McDonough V; Nickels JT
    J Biol Chem; 2018 Apr; 293(16):5956-5974. PubMed ID: 29491146
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Zhang Z; Zhou H; Guan M; Zhou X; Liang X; Lv Y; Bai L; Zhang J; Gong P; Liu T; Yi H; Wang J; Zhang L
    Br J Nutr; 2021 May; 125(10):1081-1091. PubMed ID: 32718364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.